Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey

Objective: To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. Methods: The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications S...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gynecologic oncology 2024-01, Vol.35 (1), p.1
Main Authors: Ji Hyun Kim, Yumi Lee, Da-young Kim, Sinae Kim, Sang-soo Seo, Sokbom Kang, Sang-yoon Park, Myong Cheol Lim
Format: Article
Language:Korean
Subjects:
Compliance
Ovarian Cancer
PARP Inhibitor
Survey
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 1
container_start_page 1
container_title Journal of gynecologic oncology
container_volume 35
creator Ji Hyun Kim
Yumi Lee
Da-young Kim
Sinae Kim
Sang-soo Seo
Sokbom Kang
Sang-yoon Park
Myong Cheol Lim
description Objective: To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. Methods: The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. Results: Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p
format article
fullrecord <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_4071171</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>4071171</kiss_id><sourcerecordid>4071171</sourcerecordid><originalsourceid>FETCH-kiss_primary_40711713</originalsourceid><addsrcrecordid>eNp9jL0KwkAQhK9Q8PcJbPYFAhejJtgFUSxF7GWNG1yNd2H3FAI-vAlYWwwDM99Mzwzn1i4jm2R2YEaqd2tXqc3mQ_PJrzcScgWBL-GQHw_A7sYXDl6g7CTehYodwRPZBXLYsaEdYd20LNTCT5QGqOY2rRgr8G8URgdFx8oaEArxqpFSEdi7ltCXvKmZmH6JldL052Mz221Pm330YNXz7_i8sGkcp3Hyv_0CbqJJdw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey</title><source>PubMed Central</source><creator>Ji Hyun Kim ; Yumi Lee ; Da-young Kim ; Sinae Kim ; Sang-soo Seo ; Sokbom Kang ; Sang-yoon Park ; Myong Cheol Lim</creator><creatorcontrib>Ji Hyun Kim ; Yumi Lee ; Da-young Kim ; Sinae Kim ; Sang-soo Seo ; Sokbom Kang ; Sang-yoon Park ; Myong Cheol Lim</creatorcontrib><description>Objective: To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. Methods: The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. Results: Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p&lt;0.001) were associated with high adherence to PARP inhibitors. Conclusion: Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.</description><identifier>ISSN: 2005-0380</identifier><language>kor</language><publisher>대한부인종양학회</publisher><subject>Compliance ; Ovarian Cancer ; PARP Inhibitor ; Survey</subject><ispartof>Journal of gynecologic oncology, 2024-01, Vol.35 (1), p.1</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Ji Hyun Kim</creatorcontrib><creatorcontrib>Yumi Lee</creatorcontrib><creatorcontrib>Da-young Kim</creatorcontrib><creatorcontrib>Sinae Kim</creatorcontrib><creatorcontrib>Sang-soo Seo</creatorcontrib><creatorcontrib>Sokbom Kang</creatorcontrib><creatorcontrib>Sang-yoon Park</creatorcontrib><creatorcontrib>Myong Cheol Lim</creatorcontrib><title>Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey</title><title>Journal of gynecologic oncology</title><addtitle>Journal of Gynecologic Oncology (JGO)</addtitle><description>Objective: To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. Methods: The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. Results: Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p&lt;0.001) were associated with high adherence to PARP inhibitors. Conclusion: Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.</description><subject>Compliance</subject><subject>Ovarian Cancer</subject><subject>PARP Inhibitor</subject><subject>Survey</subject><issn>2005-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9jL0KwkAQhK9Q8PcJbPYFAhejJtgFUSxF7GWNG1yNd2H3FAI-vAlYWwwDM99Mzwzn1i4jm2R2YEaqd2tXqc3mQ_PJrzcScgWBL-GQHw_A7sYXDl6g7CTehYodwRPZBXLYsaEdYd20LNTCT5QGqOY2rRgr8G8URgdFx8oaEArxqpFSEdi7ltCXvKmZmH6JldL052Mz221Pm330YNXz7_i8sGkcp3Hyv_0CbqJJdw</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Ji Hyun Kim</creator><creator>Yumi Lee</creator><creator>Da-young Kim</creator><creator>Sinae Kim</creator><creator>Sang-soo Seo</creator><creator>Sokbom Kang</creator><creator>Sang-yoon Park</creator><creator>Myong Cheol Lim</creator><general>대한부인종양학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20240101</creationdate><title>Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey</title><author>Ji Hyun Kim ; Yumi Lee ; Da-young Kim ; Sinae Kim ; Sang-soo Seo ; Sokbom Kang ; Sang-yoon Park ; Myong Cheol Lim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_40711713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2024</creationdate><topic>Compliance</topic><topic>Ovarian Cancer</topic><topic>PARP Inhibitor</topic><topic>Survey</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ji Hyun Kim</creatorcontrib><creatorcontrib>Yumi Lee</creatorcontrib><creatorcontrib>Da-young Kim</creatorcontrib><creatorcontrib>Sinae Kim</creatorcontrib><creatorcontrib>Sang-soo Seo</creatorcontrib><creatorcontrib>Sokbom Kang</creatorcontrib><creatorcontrib>Sang-yoon Park</creatorcontrib><creatorcontrib>Myong Cheol Lim</creatorcontrib><collection>KISS</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Journal of gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ji Hyun Kim</au><au>Yumi Lee</au><au>Da-young Kim</au><au>Sinae Kim</au><au>Sang-soo Seo</au><au>Sokbom Kang</au><au>Sang-yoon Park</au><au>Myong Cheol Lim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey</atitle><jtitle>Journal of gynecologic oncology</jtitle><addtitle>Journal of Gynecologic Oncology (JGO)</addtitle><date>2024-01-01</date><risdate>2024</risdate><volume>35</volume><issue>1</issue><spage>1</spage><pages>1-</pages><issn>2005-0380</issn><abstract>Objective: To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution. Methods: The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence. Results: Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors. In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528-15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283-8.940; p=0.014), and a lower score on the quality-of-life assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027-1.086; p&lt;0.001) were associated with high adherence to PARP inhibitors. Conclusion: Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.</abstract><pub>대한부인종양학회</pub><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2005-0380
ispartof Journal of gynecologic oncology, 2024-01, Vol.35 (1), p.1
issn 2005-0380
language kor
recordid cdi_kiss_primary_4071171
source PubMed Central
subjects Compliance
Ovarian Cancer
PARP Inhibitor
Survey
title Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A43%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20of%20PARP%20inhibitor%20for%20frontline%20maintenance%20therapy%20in%20primary%20epithelial%20ovarian%20cancer:%20a%20cross-sectional%20survey&rft.jtitle=Journal%20of%20gynecologic%20oncology&rft.au=Ji%20Hyun%20Kim&rft.date=2024-01-01&rft.volume=35&rft.issue=1&rft.spage=1&rft.pages=1-&rft.issn=2005-0380&rft_id=info:doi/&rft_dat=%3Ckiss%3E4071171%3C/kiss%3E%3Cgrp_id%3Ecdi_FETCH-kiss_primary_40711713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=4071171&rfr_iscdi=true